CytoMed Therapeutics Limited (GDTC), a clinical-stage biopharmaceutical company specializing in cell-based immunotherapies, has announced a significant collaboration with SunAct Cancer Institute Private Limited, based in Mumbai, India. This partnership, formalized through a Business & Research Collaboration Agreement (BRCA), aims to investigate the potential of CytoMed's proprietary allogeneic gamma delta T cells in the treatment of solid cancers.
Key Highlights of the Collaboration:
- Objective: To assess the safety, efficacy, and tolerability of allogeneic gamma delta T cells in cancer treatment.
- Phase 2 Trial: An investigator-initiated trial will be conducted in India as part of this collaboration.
- Leadership Statements: Dr. Vijay Patil, founder of SunAct, emphasized the collaboration's role in accelerating research towards affordable and effective cancer treatments in India. Peter Choo, CytoMed's Chairman, highlighted the partnership's importance in expanding the global accessibility of their cancer therapeutics.
- Roles and Responsibilities: CytoMed will provide scientific support and manufacture the investigational product, while SunAct will oversee the local execution of the clinical trial.
- Agreement Duration: The BRCA is set for a five-year term, with the goal of making significant progress in cancer immunotherapy.
This collaboration represents a pivotal step forward in the quest for innovative cancer treatments, particularly in making such therapies more accessible in regions like India. The agreement not only underscores the commitment of both organizations to advancing cancer research but also highlights the potential of allogeneic gamma delta T cells as a promising avenue in the fight against solid tumors.
